Preprocedural mouthwashes for infection control in dentistry-an update
© 2023. The Author(s)..
OBJECTIVES: Aerosols and splatter are routinely generated in dental practice and can be contaminated by potentially harmful bacteria or viruses such as SARS-CoV-2. Therefore, preprocedural mouthwashes containing antiseptic agents have been proposed as a potential measure for infection control in dental practice. This review article aims to summarize the clinical (and, if insufficient, preclinical) evidence on preprocedural mouthwashes containing antiseptic agents and to draw conclusions for dental practitioners.
METHODS: Literature on preprocedural mouthwashes for reduction of bacterial or viral load in dental aerosols was searched and summarized.
RESULTS: Preprocedural mouthwashes, particularly those containing chlorhexidine digluconate (CHX), cetylpyridinium chloride (CPC), or essential oils (EO), can significantly reduce the bacterial load in dental aerosols. With respect to viruses such as HSV-1, there are too little clinical data to draw any clear recommendations. On the other hand, clinical data is consolidating that CPC-containing mouthwashes can temporarily reduce the intraoral viral load and infectivity in SARS-CoV-2 positive individuals. Nevertheless, potential risks and side effects due to regular antiseptic use such as ecological effects or adaptation of bacteria need to be considered.
CONCLUSIONS: The use of preprocedural mouthwashes containing antiseptics can be recommended according to currently available data, but further studies are needed, particularly on the effects on other viruses besides SARS-CoV-2. When selecting a specific antiseptic, the biggest data basis currently exists for CHX, CPC, EO, or combinations thereof.
CLINICAL RELEVANCE: Preprocedural mouthwashes containing antiseptics can serve as part of a bundle of measures for protection of dental personnel despite some remaining ambiguities and in view of potential risks and side effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Clinical oral investigations - 27(2023), Suppl 1 vom: 20. Juni, Seite 33-44 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Weber, Johanna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Infective Agents, Local |
|---|
| Anmerkungen: |
Date Completed 21.06.2023 Date Revised 21.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00784-023-04953-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355829541 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355829541 | ||
| 003 | DE-627 | ||
| 005 | 20231226065157.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00784-023-04953-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355829541 | ||
| 035 | |a (NLM)37079156 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Weber, Johanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preprocedural mouthwashes for infection control in dentistry-an update |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2023 | ||
| 500 | |a Date Revised 21.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a OBJECTIVES: Aerosols and splatter are routinely generated in dental practice and can be contaminated by potentially harmful bacteria or viruses such as SARS-CoV-2. Therefore, preprocedural mouthwashes containing antiseptic agents have been proposed as a potential measure for infection control in dental practice. This review article aims to summarize the clinical (and, if insufficient, preclinical) evidence on preprocedural mouthwashes containing antiseptic agents and to draw conclusions for dental practitioners | ||
| 520 | |a METHODS: Literature on preprocedural mouthwashes for reduction of bacterial or viral load in dental aerosols was searched and summarized | ||
| 520 | |a RESULTS: Preprocedural mouthwashes, particularly those containing chlorhexidine digluconate (CHX), cetylpyridinium chloride (CPC), or essential oils (EO), can significantly reduce the bacterial load in dental aerosols. With respect to viruses such as HSV-1, there are too little clinical data to draw any clear recommendations. On the other hand, clinical data is consolidating that CPC-containing mouthwashes can temporarily reduce the intraoral viral load and infectivity in SARS-CoV-2 positive individuals. Nevertheless, potential risks and side effects due to regular antiseptic use such as ecological effects or adaptation of bacteria need to be considered | ||
| 520 | |a CONCLUSIONS: The use of preprocedural mouthwashes containing antiseptics can be recommended according to currently available data, but further studies are needed, particularly on the effects on other viruses besides SARS-CoV-2. When selecting a specific antiseptic, the biggest data basis currently exists for CHX, CPC, EO, or combinations thereof | ||
| 520 | |a CLINICAL RELEVANCE: Preprocedural mouthwashes containing antiseptics can serve as part of a bundle of measures for protection of dental personnel despite some remaining ambiguities and in view of potential risks and side effects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Infection control | |
| 650 | 4 | |a Mouth rinse | |
| 650 | 4 | |a Mouthwash | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Mouthwashes |2 NLM | |
| 650 | 7 | |a Anti-Infective Agents, Local |2 NLM | |
| 650 | 7 | |a Chlorhexidine |2 NLM | |
| 650 | 7 | |a R4KO0DY52L |2 NLM | |
| 650 | 7 | |a Oils, Volatile |2 NLM | |
| 650 | 7 | |a Cetylpyridinium |2 NLM | |
| 650 | 7 | |a CUB7JI0JV3 |2 NLM | |
| 700 | 1 | |a Bonn, Eva L |e verfasserin |4 aut | |
| 700 | 1 | |a Auer, David L |e verfasserin |4 aut | |
| 700 | 1 | |a Kirschneck, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Buchalla, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Scholz, Konstantin J |e verfasserin |4 aut | |
| 700 | 1 | |a Cieplik, Fabian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical oral investigations |d 1998 |g 27(2023), Suppl 1 vom: 20. Juni, Seite 33-44 |w (DE-627)NLM094938687 |x 1436-3771 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:Suppl 1 |g day:20 |g month:06 |g pages:33-44 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00784-023-04953-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e Suppl 1 |b 20 |c 06 |h 33-44 | ||